Company Profile

Vaxess Technologies Inc (AKA: VAXESS TECHNOLOGIES )
Profile last edited on: 3/14/2023      CAGE: 6SPN3      UEI: HNLJN8YZPVJ3

Business Identifier: Biomedical innovations: focus on improving vaccines access
Year Founded
2011
First Award
2015
Latest Award
2023
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

700 Main Street
Cambridge, MA 02139
   (857) 928-0327
   N/A
   www.vaxess.com
Location: Single
Congr. District: 07
County: Suffolk

Public Profile

Vaxess Technologies, Inc. was launched by a team of Harvard graduate students developing a suite of vaccines on the MIMIX sustained dermal delivery platform combineing high temperature stability, improved efficacy, and simplified delivery to improve global vaccine access. Based in technology developed at Tufts, the effort has been to use a silk-derived protein to make make vaccines that are both temperature stable and soluble - effectively removing the need for refrigeration and eliminating the need for cold-chain transport. This stabilization of vaccines such that they can be stored and shipped without refrigeration also permits use of a novel sustained release micro-needle for improved vaccine delivery. The potential impact of the Vaxess effort overall not only lowers the cost of vaccine distribution, but also increase access to life-saving products.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
50-74
Revenue Range
5M-7.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $2,845,450
Project Title: Microarray Patch for Broadly Protective Seasonal Influenza Vaccination
2021 2 NIH $2,297,098
Project Title: Improved Influenza Vaccine Efficacy Through Infection Mimicry
2020 1 NSF $256,000
Project Title: At home, single dose mRNA vaccine patch (COVID-19)
2018 2 NIH $1,724,990
Project Title: Silk-Based Biospecimen Stabilization for Exposure Assessment Diagnostics
2018 2 NSF $1,559,999
Project Title: Silk: a New Approach to Developing a Heat-stable Rotavirus Vaccine

Key People / Management

  Michael A Schrader -- Co-Founder, CEO

  Patrick Ho -- Co-Founder, Vp Operations & Legal Affairs

  David Kaplan -- Scientific Co-Founder

  Jonathan August Kluge

  Kathryn Kosuda -- Co-Founder, Chief Scientific Officer VP R&D

  Fiorenzo Omenetto -- Scientific Co-Founder

  Livio Valenti -- Co-Founder, Vp Policy & Strategy